Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world multicenter study of anisodine hydrobromide injection in acute ischemic stroke
ChiCTR1900027517Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anisodine in ischemic stroke (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Proportion of patients with adverse outcome at 90 days. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
anisodine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR1900027517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027517.